Research Title: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-Related Macular Degeneration (LUCERNE)
Sponsor: Genentech, Inc. / Hoffmann-La Roche
Principal Investigator: Robert A. Stoltz, M.D., Ph.D.
Description: This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD).
Start Date: April 2019
Project Personnel: Leslie Marcus, CCRC; Caitlin Harrison, CCRC, COA; Stephanie Campbell, CRC, COA
Location(s): Marietta; 833 Campbell Hill Street, Suite 300, Marietta, GA 30060